GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BNTX
BioNTech is a German biotech company that made history as the co-creator of the first mRNA vaccine against COVID-19. Its stock price reflects its dramatic rise during the pandemic and the subsequent challenge: proving its technology can also defeat other diseases, such as cancer.
Share prices of companies in the market segment - Pharma immune
BioNTech operates in the mRNA therapeutics development segment. We classify the company as a Pharma-immune company. The chart below reflects the overall dynamics of this innovative segment, where, following the success of the COVID-19 vaccine, investors are anticipating new breakthroughs, particularly in oncology.
Broad Market Index - GURU.Markets
BioNTech is a German biotech company that, together with Pfizer, developed one of the first mRNA vaccines against COVID-19 and is now focusing on oncology. It is a component of the GURU.Markets index. The chart below shows the US market. See how BioNTech shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
BNTX - Daily change in the company's share price BNTX
BioNTech is a German biotech company that, together with Pfizer, developed one of the first mRNA vaccines against COVID-19. Its daily share price change reflects its high volatility. This metric is a key component in the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
BioNTech SE is a biotech company best known for its mRNA vaccine. This chart reflects the sector's high volatility. Comparing it to BNTX's performance helps understand how much its future depends on the success of its oncology portfolio versus overall industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
BioNTech is a German biotech company that gained worldwide recognition for developing an mRNA vaccine against COVID-19 in partnership with Pfizer. The biotech sector is extremely volatile. The chart below reflects the average fluctuations in this industry, providing context for evaluating BioNTech shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BNTX
BioNTech, renowned for its COVID-19 vaccine partnership with Pfizer, has been actively investing its proceeds over the past year into developing a portfolio of mRNA-based oncology drugs. Its year-over-year share price performance reflects the market's appreciation of this long-term strategy.
Annual dynamics of market capitalization of the market segment - Pharma immune
BioNTech SE, which rose to global fame thanks to its mRNA COVID-19 vaccine developed with Pfizer, is now using its technology to create cancer drugs. Its future depends on the success of this transition. The chart below shows how the market views the potential of its innovative mRNA platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioNTech is a biotech company that gained worldwide recognition for its mRNA vaccine against COVID-19. Its current performance is determined by its ability to apply its revolutionary technology to the development of new drugs, primarily in oncology. The chart below shows how the market is assessing the company's transition from the pandemic to a sustainable biopharmaceutical model.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BNTX
The value of BioNTech, the biotech company renowned for its mRNA COVID-19 vaccine, now depends on its R&D cycle. Monthly fluctuations on the chart reflect progress in developing its cancer and other mRNA-based vaccines, which are key to its future post-pandemic.
Monthly dynamics of market capitalization of the market segment - Pharma immune
BioNTech SE made history as the co-developer of one of the first mRNA vaccines against COVID-19, but its focus is on oncology. The dynamics of the immunopharmaceutical sector, presented in the chart, reflects investor sentiment toward risky but potentially breakthrough technologies. Against this backdrop, it's possible to assess how the market perceives the long-term prospects of BioNTech's platform beyond the pandemic.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech companies often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does BioNTech move in sync with it, or are breakthroughs in its R&D pipeline creating a completely independent story for its stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BNTX
BioNTech, a biotech company renowned for its mRNA COVID-19 vaccine, is experiencing high volatility. Weekly stock price movements reflect news about clinical trials of new drugs, particularly in oncology, and changes in the epidemiological situation.
Weekly dynamics of market capitalization of the market segment - Pharma immune
BioNTech, a pioneer in mRNA technology, often moves in tandem with overall sentiment in the biotech sector. This chart allows us to compare its volatility with the industry's overall performance, distinguishing reactions to general sector news from sharp movements driven by BioNTech-specific clinical trial news.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioNTech is a biotech company that gained worldwide recognition for its mRNA COVID-19 vaccine. Its shares follow the rhythm of development news. The chart will show how BioNTech's performance is unaffected by general market fluctuations, driven by its unique scientific and commercial news.
Market capitalization of the company, segment and market as a whole
BNTX - Market capitalization of the company BNTX
BioNTech's chart is a living history of a scientific breakthrough that changed the world. Its market cap, soaring on the success of its mRNA COVID-19 vaccine, now reflects investors' faith in this technology's ability to defeat cancer and other diseases. Every movement on the chart is a reaction to news from the labs where the medicine of the future is being created.
BNTX - Share of the company's market capitalization BNTX within the market segment - Pharma immune
BioNTech is a biotech company that gained global recognition for developing one of the first and most effective mRNA vaccines against COVID-19, in partnership with Pfizer. Its market capitalization reflects its leadership in mRNA technologies. The chart below shows how the market views the potential of its platform for developing new vaccines and drugs.
Market capitalization of the market segment - Pharma immune
BioNTech, a Pfizer partner, rose to global prominence for developing one of the first mRNA vaccines against COVID-19. The chart below shows the market capitalization of the entire biotech sector. Its dramatic rise during the pandemic is a story of how a scientific breakthrough can transform the valuation of an entire industry.
Market capitalization of all companies included in a broad market index - GURU.Markets
BioNTech made history as the creator of one of the first mRNA vaccines against COVID-19. Its market capitalization chart is a stunning story of scientific breakthrough. It demonstrates how a biotech company can quickly take off and become a significant player in the global economy thanks to a single revolutionary technology.
Book value capitalization of the company, segment and market as a whole
BNTX - Book value capitalization of the company BNTX
BioNTech's book value has skyrocketed thanks to the success of its COVID-19 vaccine. The chart below illustrates this surge, reflecting capital accumulation and investments in new production facilities and R&D. It's a visual history of the biotech startup's transformation into a global pharmaceutical player.
BNTX - Share of the company's book capitalization BNTX within the market segment - Pharma immune
BioNTech is a biotech company renowned for its mRNA vaccine. Its strength lies in cutting-edge research, but vaccine production requires state-of-the-art facilities. The asset share chart shows how the company is investing in the unique physical infrastructure needed to create the medicine of the future.
Market segment balance sheet capitalization - Pharma immune
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. BioNTech, famous for its mRNA vaccine, is also building its own factories. This makes it capital-intensive, but gives it control over production, which is critical for creating the medicine of the future.
Book value of all companies included in the broad market index - GURU.Markets
BioNTech is the company behind one of the first and most effective mRNA vaccines against COVID-19. Its assets are not just factories, but a cutting-edge scientific platform capable of rapidly developing new drugs. The chart shows the material weight behind this biotech revolution.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BNTX
BioNTech SE is a biotech company that rose to global prominence thanks to its mRNA COVID-19 vaccine. Its premium reflects its ability to apply its revolutionary mRNA platform to the development of vaccines and cancer treatments.
Market to book capitalization ratio in a market segment - Pharma immune
BioNTech SE made history as the developer of one of the first mRNA vaccines against COVID-19. Its value is based on its revolutionary technology platform. This chart shows how its market valuation, reflecting the potential of mRNA technologies to treat other diseases, is many times greater than its book value.
Market to book capitalization ratio for the market as a whole
BioNTech is a biotech company that gained worldwide recognition for developing the first mRNA vaccine against COVID-19 in partnership with Pfizer. Its core value lies not in its manufacturing facilities, but in its cutting-edge scientific platform and intellectual property. The chart shows how the market values its technology's potential for creating new vaccines and cancer treatments, rather than its current assets.
Debts of the company, segment and market as a whole
BNTX - Company debts BNTX
BioNTech, the biotech company best known for its mRNA COVID-19 vaccine, is using its financial resources to expand its portfolio of oncology and infectious disease drugs. This chart shows how the company is investing the vast proceeds from its vaccine into long-term, risky research to develop new drugs.
Market segment debts - Pharma immune
BioNTech, a German biotech company, gained worldwide recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. Revenue from the vaccine has allowed the company to build a solid financial foundation. This chart shows how the company is now managing its capital, investing in the development of new drugs, including those for cancer treatment.
Market debt in general
BioNTech SE is a German biotech company that gained worldwide recognition for developing an mRNA vaccine against COVID-19. Having generated massive revenues, the company faces the challenge of effectively investing these funds in new developments. Its minimal debt compared to the market demonstrates its enormous financial strength for implementing its ambitious research program.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BNTX
BioNTech, which gained global recognition for its mRNA vaccine, is now investing heavily in developing new drugs, including those for cancer. This chart shows how the company is funding its ambitious research. Its capital structure demonstrates its ability to transform temporary success into long-term technological leadership.
Market segment debt to market segment book capitalization - Pharma immune
BioNTech made history as the developer of one of the first mRNA vaccines against COVID-19. This chart shows the debt burden in the immunopharmaceutical sector. It helps us understand how companies in this cutting-edge industry finance expensive research and clinical trials that could change the future of medicine, and how BioNTech manages its capital.
Debt to book value of all companies in the market
BioNTech, the creator of one of the first mRNA vaccines, is at the forefront of science. This chart shows the overall debt level across the market. It allows one to compare BioNTech's financial model, which requires massive investments in R&D, with the more conservative debt policies of established companies in the general economy.
P/E of the company, segment and market as a whole
P/E - BNTX
This chart from BioNTech SE, a biotech company renowned for developing an mRNA vaccine against COVID-19, shows the valuation of its innovative platform. The company's profitability is highly dependent on the success of its developments. This metric reflects investor expectations for future mRNA-based products in oncology and other fields.
P/E of the market segment - Pharma immune
BioNTech is a German biotech company that, together with Pfizer, developed one of the first and most effective COVID-19 vaccines based on mRNA technology. The company continues its oncology research. This chart illustrates the average valuation in the biotech sector, where investors are betting on revolutionary scientific platforms with enormous potential.
P/E of the market as a whole
BioNTech made history as the developer of one of the first and most effective mRNA vaccines against COVID-19. The company is now using its platform to develop drugs for cancer and other diseases. This chart shows overall market sentiment. Comparisons with it allow us to see how BioNTech's valuation depends on its future scientific breakthroughs rather than on general economic or biotech trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BNTX
BioNTech is a biotech company that gained worldwide recognition for developing one of the first mRNA vaccines against COVID-19, in partnership with Pfizer. This chart reflects market expectations for the future of mRNA technology. The valuation depends on the success of its developments in oncology and other infectious diseases, which will determine its revenue post-pandemic.
%20P%2FE%20BNTX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BNTX&v=1772603691354 "Chart of the company's future (projected) P/E BNTX")
Future (projected) P/E of the market segment - Pharma immune
BioNTech is a German biotech company that gained global recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. This chart compares the company's future profitability expectations with those for the pharmaceutical sector. It reflects how the market views their ability to use mRNA technology to create new drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772603691397 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
BioNTech, a German biotech company, is renowned for developing one of the first mRNA vaccines against COVID-19. Its future depends on the success of its research platform. This graph of overall market expectations influences BioNTech through the assessment of the entire biotech sector and investor willingness to fund long-term, risky research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772603691436 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BNTX
BioNTech is a German biotech company that gained global recognition for developing an mRNA vaccine against COVID-19 in partnership with Pfizer. Its financial results are directly dependent on vaccine sales and the success of its drug development efforts, particularly in oncology. This chart shows a unique story from scientific breakthrough to global commercial success.
Profit of companies in the market segment - Pharma immune
BioNTech, renowned for its mRNA vaccine, has become a symbol of the biotech revolution. Its future revenue depends on the success of new developments in oncology and other fields. This chart shows how one company's breakthrough innovations can radically change the financial landscape of the entire pharmaceutical industry, creating massive profits in a new segment.
Overall market profit
BioNTech is a biotech company that gained worldwide recognition for developing an mRNA vaccine against COVID-19. Its future success depends on innovations in oncology and other diseases. The company's business is driven by scientific breakthroughs, not economic cycles, so its dynamics may differ significantly from the overall picture presented in the chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BNTX
BioNTech made history as the developer of one of the first and most effective mRNA vaccines against COVID-19. This chart shows future revenue projections. Analysts' expectations are now focused on the company's ability to leverage its revolutionary mRNA platform to create new vaccines and cancer treatments, which will determine its revenue in the post-COVID era.
%20profit%20of%20the%20company%20BNTX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BNTX&v=1772603691580 "Graph of future (projected) profit of the company BNTX")
Future (predicted) profit of companies in the market segment - Pharma immune
BioNTech, known for its pioneering mRNA technology, played a key role in developing the COVID-19 vaccine with Pfizer. This chart shows the revenue forecast for the entire immunopharmaceutical industry. It reflects expectations for the development of personalized treatments for cancer and other diseases. This trend is important for assessing the potential of BioNTech's future products.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772603691627 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
BioNTech made history as the developer of one of the first mRNA vaccines against COVID-19. The company is now using its technology to create oncology and other treatments. Its success depends on scientific breakthroughs, but the overall economic situation, as illustrated here, influences the level of government funding for healthcare and investor willingness to invest in risky biotechnologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772603691634 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BNTX
BioNTech is a German biotech company that rose to global prominence for developing one of the first mRNA vaccines against COVID-19 in collaboration with Pfizer. This chart shows how investors are assessing its revenue post-pandemic, trying to determine whether its innovative mRNA platform can generate new successful products in oncology and other fields.
P/S market segment - Pharma immune
BioNTech made history as a co-developer of one of the first and most effective mRNA vaccines against COVID-19. The company is now using its platform to create oncology and other vaccines. This chart shows the average revenue estimate in the biotech sector, which helps us understand the enormous premium the market is paying for BioNTech's revolutionary mRNA technology.
P/S of the market as a whole
BioNTech is a German biotech company that, together with Pfizer, developed one of the first and most effective mRNA vaccines against COVID-19. The company is now using its platform to develop cancer drugs. This market valuation chart helps understand the premium investors are willing to pay for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BNTX
BioNTech is a biotech company that gained global recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. Future revenue depends on the success of its oncology and infectious disease programs based on mRNA technology. This chart reflects investor confidence in the potential of its innovative platform for drug discovery.
%20P%2FS%20BNTX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BNTX&v=1772603691831 "The graph of the company's future (projected) P/S BNTX")
Future (projected) P/S of the market segment - Pharma immune
BioNTech is a biotech company that gained global recognition for developing one of the first mRNA vaccines against COVID-19 in collaboration with Pfizer. The company is now using its platform to develop drugs for cancer and other diseases. This chart shows how the market estimates its future revenue after the pandemic, betting on the success of its innovative mRNA technology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772603691899 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
BioNTech made history as the developer of one of the first mRNA vaccines against COVID-19. The company is now using this technology to create cancer treatments. The market optimism, evident in this chart, is partly based on faith in biotech breakthroughs. BioNTech's success could transform medicine and drive growth for the entire healthcare industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772603691938 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BNTX
BioNTech is a biotechnology company that gained global recognition for developing one of the first mRNA vaccines against COVID-19 in collaboration with Pfizer. Its revenue depends on sales of this vaccine and progress in developing other mRNA-based treatments, particularly in oncology. The chart shows the financial impact of its groundbreaking scientific achievements.
Sales of companies in the market segment - Pharma immune
BioNTech is a biotech company that gained worldwide recognition for developing one of the first mRNA vaccines against COVID-19 in partnership with Pfizer. Its business is based on an innovative mRNA platform, which is also used to develop cancer and other vaccines. This chart highlights the potential of the biotech sector, where breakthrough technologies can radically change medicine.
Overall market sales
BioNTech is a biotech company renowned for developing an mRNA vaccine against COVID-19. Its future now depends on the success of other drugs in development, particularly in oncology. While this business is less dependent on economic cycles, the overall economic situation, as reflected in the chart, influences government funding and investment in biotech.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BNTX
BioNTech is a German biotech company that gained global recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. The company's future depends on the success of its oncology and infectious disease programs. This chart shows how analysts assess the potential of new drugs in development, forecasting future revenue sources after the pandemic.
%20sales%20of%20the%20company%20BNTX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BNTX&v=1772603692188 "Schedule of future (projected) sales of the company BNTX")
Future (projected) sales of companies in the market segment - Pharma immune
BioNTech is a German biotech company that gained worldwide recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. This chart provides an outlook for the pharmaceutical industry, allowing us to assess how the company is using its revolutionary mRNA platform to create new vaccines and cancer treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772603692225 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
BioNTech SE, a biotech company known for its mRNA vaccine, sees this chart as an indicator of healthcare systems' readiness for innovation. The stable economic growth predicted here provides funding for the development and procurement of advanced therapeutics, such as the personalized cancer vaccines BioNTech is developing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772603692243 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BNTX
BioNTech is a German biotech company that gained global recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. Their future depends on the success of other drugs based on their innovative platform. This chart shows how a biotech breakthrough can lead to explosive profitability, and how the company reinvests these revenues into new developments.
Market segment marginality - Pharma immune
BioNTech is a German biotech company that gained global recognition for developing one of the first mRNA vaccines against COVID-19 in collaboration with Pfizer. This chart shows its profitability. The company's success after the pandemic depends on its ability to commercialize its mRNA platform for the development of vaccines and drugs against cancer and other diseases.
Market marginality as a whole
BioNTech made history as the developer of one of the first mRNA vaccines against COVID-19. Its future now depends on the success of other drugs in development. The company's success is determined by scientific breakthroughs, not economic cycles. This graph of total market returns demonstrates how biotech successes can be unaffected by the overall market environment.
Employees in the company, segment and market as a whole
Number of employees in the company BNTX
BioNTech made history as the developer of one of the first and most effective mRNA vaccines against COVID-19. This chart clearly illustrates the company's transformation. The explosive growth in staff during the pandemic reflected the need to scale production, and the subsequent dynamics demonstrate the redirection of resources toward developing a broad portfolio of oncology and other vaccines.
Share of the company's employees BNTX within the market segment - Pharma immune
BioNTech is a biotechnology company that gained global recognition for developing one of the first mRNA vaccines against COVID-19. This chart shows the percentage of leading scientists in the fields of immunology and mRNA technologies that the company attracts. This demonstrates its scientific leadership and its development into a powerful center of biopharmaceutical innovation.
Number of employees in the market segment - Pharma immune
BioNTech SE is a German biotech company that, together with Pfizer, developed one of the first and most effective mRNA vaccines against COVID-19. This chart shows the explosive growth of employment in the biotech sector. The sharp increase in the number of scientists and researchers demonstrates how a breakthrough technology can transform a company into a global leader overnight.
Number of employees in the market as a whole
BioNTech made history as the developer of one of the first mRNA vaccines against COVID-19. The company is now using this technology to create cancer treatments. This employment graph reflects the economy's ability to fund advanced medicine. A stable labor market supports public and private healthcare spending, which is essential for conducting expensive clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BNTX (BNTX)
BioNTech, which rose to global fame thanks to its development of an mRNA vaccine against COVID-19, is a shining example of a biotech company. This chart shows how the market values a scientific breakthrough. The astronomical market capitalization per employee reflects not the company's headcount, but rather the revolutionary technology and intellectual property that could transform medicine.
%20of%20the%20company%20BNTX%20(BNTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BNTX-BNTX&v=1772603692537 "Chart of market capitalization per employee (in thousands of dollars) of the company BNTX (BNTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
BioNTech (BNTX) is a biotech company that rose to global fame thanks to its mRNA vaccine (developed with Pfizer). Its value lies in its R&D platform. This chart shows the market value per employee, reflecting the (now lowered) expectations for its scientific platform.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772603692567 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
BioNTech made history as the developer of one of the first and most effective mRNA vaccines against COVID-19. This chart reflects the colossal market value per scientist and employee, demonstrating how scientific breakthroughs and innovative biotech platforms can create unprecedented shareholder value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772603692589 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BNTX (BNTX)
BioNTech is a German biotech company famous for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. This chart shows how breakthrough technology changes everything. It reflects the colossal profits a team of scientists and researchers can generate after commercializing a single blockbuster. It's an indicator of the effectiveness of their R&D platform.
%20Chart%20BNTX%20(BNTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BNTX-BNTX&v=1772603692596 "Company Profit Per Employee (in thousands of dollars) Chart BNTX (BNTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
BioNTech is a German biotech company famous for its COVID-19 "mRNA vaccine" (developed for Pfizer). This chart shows the benchmark for "Pharma immune." This benchmark has become astronomical during the pandemic, demonstrating how an R&D platform (mRNA) can generate colossal profits per scientist.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772603692623 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
BioNTech is a biotech company that gained worldwide recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. It's a science-intensive business where breakthrough innovations can generate colossal profits. This chart vividly illustrates how a scientific discovery made by a relatively small team can lead to explosive financial results.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772603692644 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BNTX (BNTX)
BioNTech is a biotech company that gained global recognition for developing an mRNA vaccine against COVID-19 in collaboration with Pfizer. This chart reflects the phenomenal success of its platform. Its astronomical revenue per employee is the result of a scientific breakthrough that enabled the rapid development and commercialization of a life-saving product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BNTX-BNTX&v=1772603692654 "Sales chart per company employee BNTX (BNTX)")
Sales per employee in the market segment - Pharma immune
BioNTech is a German biotech company famous for developing the first mRNA vaccine against COVID-19 (together with Pfizer). Their business is cutting-edge scientific R&D, primarily in oncology. This chart shows the industry average per employee income, which helps assess the commercial viability of their R&D platform.
Sales per employee for the market as a whole
BioNTech is a German biotech company that, in partnership with Pfizer, created one of the first and most successful mRNA vaccines against COVID-19. Their business is cutting-edge science (mRNA). This chart shows the colossal (albeit temporary) revenue their research team generated during the pandemic, and how they are reinvesting it in oncology.
Short shares by company, segment and market as a whole
Shares shorted by company BNTX (BNTX)
BioNTech is a German biotech company that, together with Pfizer, developed a breakthrough mRNA vaccine for COVID-19. This chart shows the bears betting on a decline. Bears are shorting BNTX, rightly believing that vaccine revenues have plummeted since the pandemic ended. Now the company must prove that its mRNA platform can create other successful treatments, which is very risky.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BNTX-BNTX&v=1772603692799 "Short Shares Chart for the Company BNTX (BNTX)")
Shares shorted by market segment - Pharma immune
BioNTech (BNTX) is a German biotech company that rose to global prominence through its collaboration with Pfizer to develop an mRNA vaccine against COVID-19. This chart shows bets against the entire biotech sector. The rising bets against the industry reflect investor skepticism about BNTX's ability to find a new blockbuster once the pandemic subsides, casting doubt on its entire mRNA platform.
Shares shorted by the overall market
BioNTech made history as the creator of one of the first mRNA vaccines. It's a biotech company whose valuation is heavily dependent on the success of clinical trials. This indicator reflects the overall "risk appetite" in the market. When fear mounts, investors often sell off biotech companies, locking in profits, regardless of the company's own news.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BNTX (BNTX)
BioNTech is a revolutionary biotech company famous for its mRNA COVID vaccine (with Pfizer). This oscillator measures the reaction to binary events. Successful Phase 2 data for their new mRNA cancer vaccine could trigger explosive growth and euphoria (above 70). Conversely, a trial failure would send the stock into oversold territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BNTX-BNTX&v=1772603692853 "RSI 14 indicator chart for the company's stock BNTX (BNTX)")
RSI 14 Market Segment - Pharma immune
BioNTech is a biotech company that rose to global prominence through its collaboration with Pfizer to develop an mRNA vaccine against COVID-19. Their primary focus is cancer immunotherapy. This chart reflects the overall hype and decline in the biotech sector. It helps distinguish BNTX's movement related to its own research from the overall industry trend.
RSI 14 for the overall market
BioNTech (BNTX) is a biotech company that gained worldwide recognition for developing an mRNA vaccine against COVID-19. They are now focusing on oncology. This chart measures the overall market "temperature." Biotech stocks, especially well-known ones like BNTX, can be highly volatile and react strongly to both investor euphoria and panic.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BNTX (BNTX)
BioNTech made history by developing an mRNA vaccine against COVID-19 (in partnership with Pfizer). Now the company is using these revenues to build a vast portfolio of cancer drugs. This chart reflects analysts' complex assessments of how quickly vaccine revenues will decline and the likelihood of success of its future oncology drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BNTX-BNTX&v=1772603692918 "A chart showing analyst consensus forecasts for the expected stock price. BNTX (BNTX)")
The difference between the consensus estimate and the actual stock price BNTX (BNTX)
BioNTech made history as a partner of Pfizer, creating one of the first and most effective mRNA vaccines against COVID-19. The company is now using this technology to develop vaccines against cancer and other diseases. This chart shows analysts' confidence in their mRNA platform post-pandemic. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BNTX-BNTX&v=1772603692935 "A chart showing the difference between the consensus forecast and the actual stock price. BNTX (BNTX)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
BioNTech is a German biotech company famous for developing an mRNA vaccine for COVID (in collaboration with Pfizer). Now, it's using this technology to fight cancer. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in the commercial success of mRNA technologies in oncology or consider it a distant prospect.
Analysts' consensus forecast for the overall market share price
BioNTech (BNTX) is a biotech company that made a breakthrough with its mRNA platform, which formed the basis of a COVID-19 vaccine. They are now applying this technology to fight cancer. This chart reflects the overall risk appetite in the market, demonstrating how much confidence experts have in the economy to fund expensive scientific research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BNTX
BioNTech is a German biotech company that has become world-renowned as a pioneer in mRNA technology, leading to the development of a breakthrough COVID-19 vaccine (in partnership with Pfizer). This chart is a complex assessment of their future. It weighs the sharp decline in vaccine revenue against the enormous expectations for their extensive R&D pipeline, particularly in oncology.
AKIMA Market Segment Index - Pharma immune
BioNTech is a German biotech company that (together with Pfizer) created the first and most successful mRNA vaccine (Comirnaty). It is currently using this R&D platform to develop cancer drugs. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does BioNTech's mRNA platform differentiate it from the average pharma company?
The AKIM Index for the overall market
BioNTech is a German biotech company that gained worldwide recognition for its breakthrough mRNA vaccine (Comirnaty), developed in partnership with Pfizer. The company is now applying this technology to oncology. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to overall economic trends.
